Hybrid Approach to Identify Druglikeness Leading Compounds against COVID-19 3CL Protease

• URL: http://arxiv.org/abs/2208.06362v3
• Date: Wed, 24 Aug 2022 09:25:25 GMT
• Title: Hybrid Approach to Identify Druglikeness Leading Compounds against COVID-19 3CL Protease
• Authors: Imra Aqeel and Abdul Majid
• Abstract summary: SARS-COV-2 is a positive single-strand RNA-based macromolecule that has caused the death of more than 6.3 million people since June 2022. It is vital to design and develop drugs for this virus and its various variants. In this paper, we developed an in-silico study-based hybrid framework to repurpose existing therapeutic agents in finding drug-like bioactive molecules that would cure Covid-19.
• Score: 0.5076419064097732
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: SARS-COV-2 is a positive single-strand RNA-based macromolecule that has caused the death of more than 6.3 million people since June 2022. Moreover, by disturbing global supply chains through lockdown, the virus has indirectly caused devastating damage to the global economy. It is vital to design and develop drugs for this virus and its various variants. In this paper, we developed an in-silico study-based hybrid framework to repurpose existing therapeutic agents in finding drug-like bioactive molecules that would cure Covid-19. We employed the Lipinski rules on the retrieved molecules from the ChEMBL database and found 133 drug-likeness bioactive molecules against SARS coronavirus 3CL Protease. Based on standard IC50, the dataset was divided into three classes active, inactive, and intermediate. Our comparative analysis demonstrated that the proposed Extra Tree Regressor (ETR) based QSAR model has improved prediction results related to the bioactivity of chemical compounds as compared to Gradient Boosting, XGBoost, Support Vector, Decision Tree, and Random Forest based regressor models. ADMET analysis is carried out to identify thirteen bioactive molecules with ChEMBL IDs 187460, 190743, 222234, 222628, 222735, 222769, 222840, 222893, 225515, 358279, 363535, 365134 and 426898. These molecules are highly suitable drug candidates for SARS-COV-2 3CL Protease. In the next step, the efficacy of bioactive molecules is computed in terms of binding affinity using molecular docking and then shortlisted six bioactive molecules with ChEMBL IDs 187460, 222769, 225515, 358279, 363535, and 365134. These molecules can be suitable drug candidates for SARS-COV-2. It is anticipated that the pharmacologist/drug manufacturer would further investigate these six molecules to find suitable drug candidates for SARS-COV-2. They can adopt these promising compounds for their downstream drug development stages.

Related papers

• Generative Active Learning for the Search of Small-molecule Protein Binders [87.106635995213]
  We introduce LambdaZero, a generative active learning approach to search for synthesizable molecules. LambdaZero learns to search over the vast space of molecules to discover candidates with a desired property. We apply LambdaZero with molecular docking to design novel small soluble molecules that inhibit the enzyme Epoxide Hydrolase 2 (sEH) LambdaZero discovers novel scaffolds of synthesizable, drug-like inhibitors for sEH.
  arXiv  Detail & Related papers  (2024-05-02T16:39:21Z)
• Drug Repurposing Targeting COVID-19 3CL Protease using Molecular Docking and Machine Learning Regression Approach [0.15346678870160887]
  The COVID-19 pandemic has initiated a global health emergency, with an exigent need for effective cure. We screened the 5903 approved drugs for their inhibition by targeting the main protease 3CL of SARS-CoV-2. We employed several machine learning regression approaches for QSAR modeling to find out some potential drugs with high binding affinities.
  arXiv  Detail & Related papers  (2023-05-25T05:34:39Z)
• Tailoring Molecules for Protein Pockets: a Transformer-based Generative Solution for Structured-based Drug Design [133.1268990638971]
  De novo drug design based on the structure of a target protein can provide novel drug candidates. We present a generative solution named TamGent that can directly generate candidate drugs from scratch for a given target.
  arXiv  Detail & Related papers  (2022-08-30T09:32:39Z)
• Accelerating Inhibitor Discovery for Multiple SARS-CoV-2 Targets with a Single, Sequence-Guided Deep Generative Framework [47.14853881703749]
  We demonstrate the broad utility of a single deep generative framework toward discovering novel drug-like inhibitor molecules. To perform target-aware design, the framework employs a target sequence-conditioned sampling of novel molecules from a generative model. The most potent spike RBD inhibitor also emerged as a rare non-covalent antiviral with broad-spectrum activity against several SARS-CoV-2 variants.
  arXiv  Detail & Related papers  (2022-04-19T17:59:46Z)
• Improved Drug-target Interaction Prediction with Intermolecular Graph Transformer [98.8319016075089]
  We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture. Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively. IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
  arXiv  Detail & Related papers  (2021-10-14T13:28:02Z)
• A Novel Framework Integrating AI Model and Enzymological Experiments Promotes Identification of SARS-CoV-2 3CL Protease Inhibitors and Activity-based Probe [8.35958386389992]
  We propose a novel framework, named AIMEE, to identify inhibitors against 3CL protease of SARS-CoV-2. From a bioactive chemical library, we have conducted two rounds of experiments and identified six novel inhibitors with a hit rate of 29.41%. We explored the interpretability of the central model in AIMEE, mapping the deep learning extracted features to domain knowledge of chemical properties.
  arXiv  Detail & Related papers  (2021-05-29T06:23:05Z)
• Genetic Constrained Graph Variational Autoencoder for COVID-19 Drug Discovery [0.0]
  We propose a new model called Genetic Constrained Graph Variational Autoencoder (GCGVAE) to solve this problem. We trained our model based on the data of various viruses' protein structure, including that of the SARS, HIV, Hep3, and MERS, and used it to generate possible drugs for SARS-CoV-2. Our generated molecules have great effectiveness in inhibiting SARS-CoV-2.
  arXiv  Detail & Related papers  (2021-04-23T16:10:15Z)
• Accelerating Antimicrobial Discovery with Controllable Deep Generative Models and Molecular Dynamics [109.70543391923344]
  CLaSS (Controlled Latent attribute Space Sampling) is an efficient computational method for attribute-controlled generation of molecules. We screen the generated molecules for additional key attributes by using deep learning classifiers in conjunction with novel features derived from atomistic simulations. The proposed approach is demonstrated for designing non-toxic antimicrobial peptides (AMPs) with strong broad-spectrum potency.
  arXiv  Detail & Related papers  (2020-05-22T15:57:58Z)
• CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models [74.58583689523999]
  We propose an end-to-end framework, named CogMol, for designing new drug-like small molecules targeting novel viral proteins. CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme. CogMol handles multi-constraint design of synthesizable, low-toxic, drug-like molecules with high target specificity and selectivity.
  arXiv  Detail & Related papers  (2020-04-02T18:17:20Z)
• Large-scale ligand-based virtual screening for SARS-CoV-2 inhibitors using deep neural networks [5.50889410189681]
  "ChemAI" is a deep neural network trained on more than 220M data points across 3.6M molecules. We screened and ranked one billion molecules from the ZINC database for favourable effects against CoV-2. We then reduced the result to the 30,000 top-ranked compounds, which are readily accessible and purchasable.
  arXiv  Detail & Related papers  (2020-03-25T15:24:09Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.